Technical Analysis for TGTX - TG Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical TGTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -3.07% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -3.07% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -3.07% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Lower Bollinger Band Support | about 23 hours ago | |
| Down 5% | 1 day ago | |
| Down 3% | 1 day ago | |
| Down 2 % | 1 day ago | |
| Fell Below Lower Bollinger Band | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 03/01/2021
TG Therapeutics, Inc. Description
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Treatment Of Cancer Pharmaceutical Products Monoclonal Antibodies Monoclonal Antibody Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20 Lymphocytes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 56.74 |
| 52 Week Low | 6.34 |
| Average Volume | 2,156,060 |
| 200-Day Moving Average | 25.81 |
| 50-Day Moving Average | 40.16 |
| 20-Day Moving Average | 52.59 |
| 10-Day Moving Average | 52.07 |
| Average True Range | 2.84 |
| ADX | 42.22 |
| +DI | 30.65 |
| -DI | 19.17 |
| Chandelier Exit (Long, 3 ATRs ) | 48.23 |
| Chandelier Exit (Short, 3 ATRs ) | 53.66 |
| Upper Bollinger Band | 55.29 |
| Lower Bollinger Band | 49.90 |
| Percent B (%b) | -0.05 |
| BandWidth | 10.25 |
| MACD Line | 3.08 |
| MACD Signal Line | 4.17 |
| MACD Histogram | -1.0885 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 54.08 | ||||
| Resistance 3 (R3) | 54.23 | 52.88 | 53.34 | ||
| Resistance 2 (R2) | 52.88 | 51.74 | 52.81 | 53.09 | |
| Resistance 1 (R1) | 51.25 | 51.04 | 50.58 | 51.11 | 52.84 |
| Pivot Point | 49.91 | 49.91 | 49.57 | 49.83 | 49.91 |
| Support 1 (S1) | 48.27 | 48.77 | 47.60 | 48.13 | 46.40 |
| Support 2 (S2) | 46.93 | 48.07 | 46.86 | 46.15 | |
| Support 3 (S3) | 45.30 | 46.93 | 45.90 | ||
| Support 4 (S4) | 45.16 |
